Busy IPO week winds down as two more biotechs — and one look­ing to im­prove clin­i­cal tri­als — file for pub­lic de­buts

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Two more biotech com­pa­nies — and one that’s com­mit­ted to sup­port­ing clin­i­cal re­search — filed for IPOs just be­fore the long week­end.

No­bel lau­re­ate Jen­nifer Doud­na’s Cari­bou Bio­sciences is pen­cil­ing in a $100 mil­lion raise to sup­port its off-the-shelf CAR-T ther­a­pies, one of which is mak­ing its way through a Phase I study in B-cell non-Hodgkin lym­phoma. Al­so look­ing for a $100 mil­lion raise is WCG Clin­i­cal Ser­vices, which es­tab­lished it­self as an al­ly to bio­phar­ma com­pa­nies and CROs back in 2012. The com­pa­ny of­fers plan­ning, pa­tient en­gage­ment, and eth­i­cal re­view ser­vices, and says it was be­hind more than 723 Covid-19 tri­als. Mean­while, transpa­cif­ic biotech Brii Bio­sciences is look­ing for its own tick­er on the Hong Kong Stock Ex­change, and says it’ll use the funds across its broad in­fec­tious dis­ease and CNS pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.